Royal Biologics Takes Diverse Approach to Autologous Live Cell Therapy

While autologous live cell therapies are not new, Royal Biologics is creating a unique value proposition through its growing ALC portfolio. With the company in the middle of a three-year growth that withstood the pandemic, we spoke to Royal Biologics CEO Salvatore Leo about the company’s technology, next steps and lessons learned during the...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us